Estee Lauder Companies Inc vs Mesoblast Limited — how do they compare? Estee Lauder Companies Inc trades at $88.01 (market cap $31.76B), while Mesoblast Limited trades at $16.68 (market cap $2.21B). The key difference: Estee Lauder Companies Inc is far larger — about 14.4× Mesoblast Limited's market cap, and Estee Lauder Companies Inc pays a 1.59% dividend while Mesoblast Limited pays none. Which is the better fit depends on your goals.
| EL | MESO | |
|---|---|---|
Market Cap | $31.76B | $2.21B |
Sector | Consumer Staples | Technology |
52-Week High | $119.61 | $20.96 |
52-Week Low | $67.23 | $12.88 |
Enterprise Value | $37.93B | $2.21B |
Dividend Yield | 1.59% | — |
Trailing returns across standard periods
Estee Lauder is the world leader in the global prestige beauty market, participating across skincare (56% of fiscal 2022 sales), makeup (26%), fragrance (14%), and haircare (4%) categories, with popular brands such as Estee Lauder, Clinique, MAC, La Mer, Jo Malone, Aveda, Bobbi Brown, Too Faced, Origins, Dr. Jart+, and The Ordinary. The firm operates in 150 countries, with 26% of fiscal 2022 revenue stemming from the Americas, 43% from Europe, the Middle East, and Africa, and 31% from Asia-Pacific. The company sells its products through department stores, travel retail, multi-brand specialty beauty stores, brand-dedicated freestanding stores, e-commerce, salons/spas, and perfumeries.
Read more on EL →Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →